ArticleRMD open2020
Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI).
Article in RMD open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Musculoskeletal manifestations in children with Behçet's syndrome: data from the AIDA Network Behçet's Syndrome Registry.Internal and emergency medicine · 2023Trial
- Elevated Serum Follistatin-Like Protein 1 Levels Correlate with Disease Activity and Severity in Behçet's Disease: A Case-Control Study.Mediterranean journal of rheumatology · 2026Article
- Management of Severe Behçet's Disease.Current rheumatology reports · 2026Review
- Article
- Pan-Immune-Inflammation Value Predicts Disease Activity and Ocular Involvement in Behçet's Disease: A Case-Control Study.Mediterranean journal of rheumatology · 2026Article
- Clinical characteristics of behçet's disease in palestine, a retrospective cohort study.BMC rheumatology · 2025Article
- High prevalence of HLA-B51 and ocular involvement in Behçet's disease: a multicenter cross-sectional study.Rheumatology international · 2025Article
- Behçet's Syndrome Overall Damage Index performance and validation in an adult Egyptian cohort.Archives of rheumatology · 2024Article
- Ocular Manifestations in Juvenile Behçet's Disease: A Registry-Based Analysis from the AIDA Network.Ophthalmology and therapy · 2024Article
- Association of high disease activity and serum IL-6 levels with the incidence of inflammatory major organ events in Behçet disease: a prospective registry study.Frontiers in immunology · 2024Article
- Effects of breast milk on Behçet's disease clinical features.Turkish journal of medical sciences · 2023Article
- Accrual of organ damage in Behçet's syndrome: trajectory, associated factors, and impact on patients' quality of life over a 2-year prospective follow-up study.Arthritis research & therapy · 2022Article
- Development and implementation of the AIDA International Registry for patients with Behçet's disease.Internal and emergency medicine · 2022Article
- Effectiveness and safety of low-dose interferon alpha-2a treatment in Behçet's Syndrome with refractory vascular or neurological involvement: a case series.Therapeutic advances in chronic disease · 2022Article
- Vasculitis damage index in Behçet's disease.Advances in rheumatology (London, England) · 2021Article
- Advances in the Treatment of Behcet's Disease.Current rheumatology reports · 2021Review
- Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome.Frontiers in medicine · 2021Article
- Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort.Arthritis research & therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and validate the evidence-based and consensus-based Behçet's Syndrome Overall Damage Index (BODI).
methodsStarting from 120 literature-retrieved preliminary items, the BODI underwent multiple Delphi rounds with an international multidisciplinary panel consisting of rheumatologists, internists, ophthalmologists, neurologists, and patient delegates until consensus was reached on the final content. The BODI was validated in a cross-sectional multicentre cohort of 228 patients with Behçet's syndrome (BS) through the study of (a) correlation between BODI and Vasculitis Damage Index (VDI) and (b) correlation between BODI and disease activity measures (ie, Behçet's Disease Current Activity Form (BDCAF), Physician Global Assessment (PGA), Patient Global Assessment (PtGA)), c) content and face validity and (d) feasibility.
resultsThe final BODI consists of 4 overarching principles and 46 unweighted-items grouped into 9 organ domains. It showed good to excellent reliability, with a mean Cohen's k of 0.84 (95% CI 0.78 to 0.90) and a mean intra-class correlation coefficient of 0.88 (95% CI 0.80 to 0.95). Overall, 128 (56.1%) patients had a BODI score ≥1, with a median score of 1.0 (range 0-14). The BODI significantly correlated with the VDI (r=0.693, p<0.001), demonstrating to effectively measure damage (construct validity), but had greater sensitivity in identifying major organ damage and did not correlate with disease activity measures (ie, BDCAF: p=0.807, PGA: p=0.820, PtGA: p=0.794) discriminating damage from the major confounding factor. The instrument was deemed credible (face validity), complete (content validity) and feasible by an independent group of clinicians.
conclusionsPending further validation, the BODI may be used to assess organ damage in patients with BS in the context of observational and controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.